Genetic Polymorphisms of Catechol-O-Methyltransferase: Association with Temporomandibular Disorders and Postoperative Pain

Aims: To evaluate the association between catechol-O-methyltransferase (COMT) gene polymorphisms and temporomandibular disorders (TMD), TMD pain, psychosocial impairment related to TMD, and postoperative pain. Methods: A total of 90 patients with a diagnosis of painful TMD and 92 matched controls were investigated for the presence of TMD, TMD pain, and psychosocial variables by the Research Diagnostic Criteria for TMD. In a prospective cohort study of 40 subjects who underwent extraction of at least one fully impacted mandibular third molar, subjects had 6 months post-surgery follow-up of postoperative pain. DNA extracted from peripheral blood was genotyped for three COMT polymorphisms (rs4680, rs6269, and rs165774) by real-time TaqMan method. The association between COMT polymorphisms and clinical variables was determined by calculating odds ratios (OR) and their 95% confidence intervals (CI). Results: Homozygous AA genotype and heterozygous variant A allele carriers (genotype AG/AA) for rs165774 polymorphism were associated with increased risk of TMD compared to wild type (wt) GG genotype (OR = 9.448, P = .006; OR = 2.088, P = .017, respectively). In addition, AA genotype was associated with increased risk of arthralgia (OR = 4.448, P = .011), myofascial pain (OR = 3.543, P = .035), and chronic TMD pain (OR = 6.173, P = .006), compared to wt genotype. AA genotype for rs6269 polymorphism was related to less postoperative chronic TMD pain (P = .025) and lower postoperative acute pain at the extraction site (P = .030). No associations with depression and somatization were observed. Conclusion: AA genotype of rs165774 could be a significant risk factor for the development of TMD and TMD pain, while AA genotype of rs6269 presents less postoperative chronic TMD pain and acute pain at a dental extraction site.

COMT; genetic polymorphisms; pain; temporomandibular disorders; third molar surgery

1. Romero-Reyes M, Uyanik JM. Orofacial pain management: Current perspectives. J Pain Res 2014;7:99–115.

2. van Selms MK, Lobbezoo F, Naeije M. Time courses of myofascial temporomandibular disorder complaints during a 12- month follow-up period. J Orofac Pain 2009;23:345–352.

3. De Leeuw R. Temporomandibular disorders. In: De Leeuw R (ed). Orofacial Pain: Guidelines for Assessment, Diagnosis, and Management, fourth edition. Chicago: Quintessence, 2008: 129–204.

4. Smith SB, Maixner DW, Greenspan JD, et al. Potential genetic risk factors for chronic TMD: Genetic associations from the OPPERA case control study. J Pain 2011;12 (suppl):T92–T101.

5. Oakley M, Vieira AR. The many faces of the genetics contribution to temporomandibular joint disorder. Orthod Craniofac Res 2008;11:125–135.

6. Meloto CB, Serrano PO, Ribeiro-DaSilva MC, Rizzatti-Barbosa CM. Genomics and the new perspectives for temporomandibular disorders. Arch Oral Biol 2011;56:1181–1189.

7. Melis M, Di Giosia M. The role of genetic factors in the etiology of temporomandibular disorders: A review. Cranio 2016; 34:43–51.

8. Kambur O, Männistö PT. Catechol-O-methyltransferase and pain. Int Rev Neurobiol 2010;95:227–279.

9. Young EE, Lariviere WR, Belfer I. Genetic basis of pain variability: Recent advances. J Med Genet 2012;49:1–9.

10. Tammimäki A, Männistö PT. Catechol-O-methyltransferase gene polymorphism and chronic human pain: A systematic review and meta-analysis. Pharmacogenet Genomics 2012;22:673–691.

11. Belfer I, Segall SK, Lariviere WR, et al. Pain modality- and sex-specific effects of COMT genetic functional variants. Pain 2013;154:1368–1376.

12. Lotta T, Vidgren J, Tilgmann C, et al. Kinetics of human soluble and membrane-bound catechol O-methyltransferase: A revised mechanism and description of the thermolabile variant of the enzyme. Biochemistry 1995;34:4202–4210.

13. Zubieta JK, Heitzeg MM, Smith YR, et al. COMT val158met genotype affects mu-opioid neurotransmitter responses to a pain stressor. Science 2003;299:1240–1243.

14. Vargas-Alarcón G, Fragoso JM, Cruz-Robles D, et al. Catechol-

O- methyltransferase gene haplotypes in Mexican and Spanish patients with fibromyalgia. Arthritis Res Ther 2007;9:R110.

15. Diatchenko L, Slade GD, Nackley AG, et al. Genetic basis for individual variations in pain perception and the development of a chronic pain condition. Hum Mol Genet 2005;14:135–143.

16. Nicholl BI, Holliday KL, Macfarlane GJ, et al. No evidence for a role of the catechol-O-methyltransferase pain sensitivity haplotypes in chronic widespread pain. Ann Rheum Dis 2010; 69:2009–2012.

17. Michelotti A, Liguori R, Toriello M, et al. Catechol-O-methyltransferase (COMT) gene polymorphisms as risk factor in temporomandibular disorders patients from Southern Italy. Clin J Pain 2014;30:129–133.

18. Meloto CB, Segall SK, Smith S, et al. COMT gene locus: New functional variants. Pain 2015;156:2072–2083.

19. Massat I, Souery D, Del-Favero J, et al. Association between COMT (Val158Met) functional polymorphism and early onset in patients with major depressive disorder in a European multicenter genetic association study. Mol Psychiatry 2005;10: 598–605.

20. Slade GD, Diatchenko L, Bhalang K, et al. Influence of psychological factors on risk of temporomandibular disorders. J DentRes 2007;86:1120–1125.

21. Antypa N, Drago A, Serretti A. The role of COMT gene variants in depression: Bridging neuropsychological, behavioral andclinical phenotypes. Neurosci Biobehav Rev 2013;37: 1597–1610.

22. Klengel T, Heck A, Pfister H, et al. Somatization in major depression--clinical features and genetic associations. Acta Psychiatr Scand 2011;124:317–328.

23. Hall KT, Tolkin BR, Chinn GM, et al. Conscientiousness is modified by genetic variation in catechol-O-methyltransferase to reduce symptom complaints in IBS patients. Brain Behav 2015;5:39–44.

24. Juhl GI, Jensen TS, Norholt SE, Svensson P. Incidence of symptoms and signs of TMD following third molar surgery: A controlled, prospective study. J Oral Rehabil 2009;36:199–209.

25. Huang GJ, Rue TC. Third-molar extraction as a risk factor for temporomandibular disorder. J Am Dent Assoc 2006;137: 1547–1554.

26. Kim H, Lee H, Rowan J, Brahim J, Dionne RA. Genetic polymorphisms in monoamine neurotransmitter systems show only weak association with acute post-surgical pain in humans. Mol Pain 2006;2:24.

27. Lee PJ, Delaney P, Keogh J, Sleeman D, Shorten GD. Catecholamine-o-methyltransferase polymorphisms are associated with postoperative pain intensity. Clin J Pain 2011;27:93–101.

28. Kambur O, Kaunisto MA, Tikkanen E, Leal SM, Ripatti S, Kalso EA. Effect of catechol-O-methyltransferase-gene (COMT) variants on experimental and acute postoperative pain in 1,000 women undergoing surgery for breast cancer. Anesthesiology 2013;119:1422–1433.

29. Hong EP, Park JW. Sample size and statistical power calculation in genetic association studies. Genomics Inform 2012; 10:117–122.

30. Dworkin SF, LeResche L. Research diagnostic criteria for temporomandibular disorders: Review, criteria, examinations and specifications, critique. J Craniomandib Disord 1992;6:301–355.

31. Lim PF, Smith S, Bhalang K, Slade GD, Maixner W. Development of temporomandibular disorders is associated with greater bodily pain experience. Clin J Pain 2010;26:116–120.

32. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: Analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21:263–265.

33. Fillingim RB, Ohrbach R, Greenspan JD, et al. Potential psychosocial risk factors for chronic TMD: Descriptive data and empirically identified domains from the OPPERA case-control study. J Pain 2011;12(suppl):T46–T60.

34. Nackley AG, Shabalina SA, Tchivileva IE, et al. Human catechol-O-methyltransferase haplotypes modulate protein expression by altering mRNA secondary structure. Science 2006; 314:1930–1933.

35. Zhang K, Gao J, An C, et al. An association study between cathechol-O-methyltransferase gene and mental retardation in the Chinese Han population. Neurosci Lett 2007;419:83–87.

36. Bortsov AV, Diatchenko L, McLean SA. Complex multilocus effects of catechol-O-methyltransferase haplotypes predict pain and pain interference 6 weeks after motor vehicle collision. Neuromolecular Med 2014;16:83–93.

37. Visscher CM, Lobbezoo F. TMD pain is partly heritable. A systematic review of family studies and genetic association studies. J Oral Rehabil 2015;42:386–399.

38. Zhang J, Ji Y, Moon I, et al. Catechol O-methyltransferase pharmacogenomics: Human liver genotype-phenotype correlation and proximal promoter studies. Pharmacogenet Genomics 2009; 19:577–587.

39. Godar SC, Bortolato M. Gene-sex interactions in schizophrenia: Focus on dopamine neurotransmission. Front Behav Neurosci 2014;8:71.

40. Smith SB, Reenilä I, Männistö PT, et al. Epistasis between polymorphisms in COMT, ESR1, and GCH1 influences COMT enzyme activity and pain. Pain 2014;155:2390–2399.

41. Schwahn C, Grabe HJ, Meyer zu Schwabedissen H, et al. The effect of catechol-O-methyltransferase polymorphisms on pain is modified by depressive symptoms. Eur J Pain 2012;16: 878–889.

42. Rut M, Machoy-Mokrzyn´ska A, Re˛cławowicz D, et al. Influence of variation in the catechol-O-methyltransferase gene on the clinical outcome after lumbar spine surgery for one-level symptomatic disc disease: A report on 176 cases. Acta Neurochir (Wien) 2014;156:245–252.

43. Omair A, Lie BA, Reikeras O, Holden M, Brox JI. Genetic contribution of catechol-O-methyltransferase variants in treatment outcome of low back pain: A prospective genetic association study. BMC Musculoskelet Disord 2012;13:76.